GlassScriptPhysician profile
Fredrick L Fox
NPI 1760408702
$5,231.30
in general payments reported to CMS, 2019-2025
26 companies · $784 in 2025
The $784 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $178 · 2021: $886 · 2022: $932 · 2023: $1,099 · 2024: $1,239 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,062 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.43 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.74 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $847.32 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $748.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $517.79 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $311.99 | 2020-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $300.24 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $263.73 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $139.35 | 2019-2024 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $124.83 | 2024-2025 | Relexxii |
| Lundbeck LLC | $114.49 | 2023-2025 | Rexulti |
| Allergan, INC. | $101.37 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $96.88 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $90.43 | 2019-2024 | Invega Sustenna |
| Tris Pharma INC | $88.58 | 2020-2025 | Onyda Xr, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $78.47 | 2023-2024 | Qelbree, Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.00 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.05 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $45.35 | 2022-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $38.33 | 2025 | |
| Noven Therapeutics, LLC | $35.38 | 2023 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $27.43 | 2019-2020 | |
| Neuronetics, INC. | $24.17 | 2024 | Neurostar Tms Therapy System |
| Biogen, INC. | $21.57 | 2024 | |
| Almatica Pharma LLC | $18.08 | 2022 | |
| Bausch Health US, LLC | $14.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.